9323 Open-label Results From Grace, A Phase 3 Double-blind, Randomized-withdrawal Study Of The Selective Glucocorticoid Receptor Modulator Relacorilant For The Treatment Of Endogenous Hypercortisolism (Cushing Syndrome)
Sign Up to like & getrecommendations! Published in 2024 at "Journal of the Endocrine Society"
DOI: 10.1210/jendso/bvae163.1287
Abstract: Abstract Disclosure: R. Pivonello: Consulting Fee; Self; Corcept Therapeutics, Recordati AG, Crinetics Pharmaceuticals, H. Lundbeck A/S. Other; Self; Corcept- Research Funding, Neurocrine Biosciences- Research Funding, Recordati AG- Research Funding, Strongbridge Biopharma- Research Funding. G. Arnaldi:… read more here.
Keywords: corcept therapeutics; board member; research; member self ... See more keywords